GlassScriptPhysician profile
Alexis C Houser
NPI 1891442422
$1,239.95
in general payments reported to CMS, 2019-2025
21 companies · $353 in 2025
The $353 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $138 · 2024: $749 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,239.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $295.13 | 2023-2025 | |
| Axsome Therapeutics, INC. | $123.52 | 2025 | Symbravo |
| Neurocrine Biosciences, INC. | $108.76 | 2023-2024 | Ingrezza, Ongentys |
| Alkermes, INC. | $107.73 | 2025 | Aristada, Lybalvi, Vivitrol |
| Neurelis, INC. | $87.99 | 2023-2024 | Valtoco |
| Novartis Pharmaceuticals Corporation | $61.35 | 2024-2025 | |
| Lilly USA, LLC | $54.62 | 2024 | Reyvow, Emgality, Amyvid |
| Jazz Pharmaceuticals INC. | $54.06 | 2023-2024 | |
| Ucb, INC. | $46.92 | 2024 | Rystiggo, Zilbrysq |
| Teva Pharmaceuticals USA, INC. | $41.80 | 2024 | Austedo Xr |
| Acadia Pharmaceuticals INC | $41.38 | 2023-2025 | Daybue, Nuplazid |
| Sk Life Science, INC. | $39.25 | 2024-2025 | |
| Ge Healthcare | $34.46 | 2024 | |
| Boston Scientific Corporation | $23.85 | 2024 | Watchman Access System |
| Biogen, INC. | $20.81 | 2024 | Vumerity, Tysabri |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $19.54 | 2024 | Aptiom |
| Amneal Pharmaceuticals LLC | $18.58 | 2024 | Rytary |
| Kyowa Kirin, INC. | $15.60 | 2024 | Nourianz |
| Janssen Pharmaceuticals, INC | $15.59 | 2025 | Invega Sustenna |
| Travere Therapeutics, INC. | $15.33 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $13.68 | 2024 | Andexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexis Houser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.